{'fraction_non_alphanumeric': 0.013757523645743766, 'fraction_numerical': 0.017196904557179708, 'mean_word_length': 5.126315789473685, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effect of the immunosuppressant FK 506 on insulin release from adult rat islets of Langerhans.

Clinical introduction of cyclosporine A (CyA) was a critical development that improved the success rate of organ transplantation.1 CyA has also been useful in the elucidation and treatment of type I diabetes as an autoimmune disease in animals2 and humans.3 Despite the impressive achievements obtained with the use of CyA. nephrotoxicity has limited its use in an autoimmune disease such as diabetes. Additionally, CyA decreases insulin synthesis and secretion from several species4–7 and decreases insulin release from human islets in vitro.8 although in vivo glucose tolerance and insulin dynamics may be normal in patients taking the drug.9 FK 506 is a new immunosuppressive agent that is more potent on a weight basis than CyA 10 and has recently been used successfully in humans undergoing organ transplantations.11 Since the drug has important potential applications in the fields of islet, whole pancreas transplantation, and immune intervention for type I diabetes, we looked at the effects of FK 506 on insulin secretion from adult rat islets of Langerhans.